NASDAQ
ATNX

Athenex Inc

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

Athenex Inc Stock Price

Vitals

Today's Low:
$0.0022
Today's High:
$0.0061
Open Price:
$0.0022
52W Low:
$0.081
52W High:
$23.8
Prev. Close:
$0.003
Volume:
2035

Company Statistics

Market Cap.:
$2.33 million
Book Value:
-0.754
Revenue TTM:
$102.82 million
Operating Margin TTM:
-72.1%
Gross Profit TTM:
$26.70 million
Profit Margin:
-100.59%
Return on Assets TTM:
-19.65%
Return on Equity TTM:
-1927.27%

Company Profile

Athenex Inc had its IPO on 2017-06-14 under the ticker symbol ATNX.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Athenex Inc has a staff strength of 269 employees.

Stock update

Shares of Athenex Inc opened at $0 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0 - $0.01, and closed at $0.01.

This is a +103.33% increase from the previous day's closing price.

A total volume of 2,035 shares were traded at the close of the day’s session.

In the last one week, shares of Athenex Inc have slipped by -95.64%.

Athenex Inc's Key Ratios

Athenex Inc has a market cap of $2.33 million, indicating a price to book ratio of 1.0771 and a price to sales ratio of 0.2001.

In the last 12-months Athenex Inc’s revenue was $102.82 million with a gross profit of $26.70 million and an EBITDA of $-71813000. The EBITDA ratio measures Athenex Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Athenex Inc’s operating margin was -72.1% while its return on assets stood at -19.65% with a return of equity of -1927.27%.

In Q4, Athenex Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 110.9%.

Athenex Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-10.45 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Athenex Inc’s profitability.

Athenex Inc stock is trading at a EV to sales ratio of 0.2695 and a EV to EBITDA ratio of -0.2144. Its price to sales ratio in the trailing 12-months stood at 0.2001.

Athenex Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$204.06 million
Total Liabilities
$114.88 million
Operating Cash Flow
$0
Capital Expenditure
$56000
Dividend Payout Ratio
0%

Athenex Inc ended 2024 with $204.06 million in total assets and $0 in total liabilities. Its intangible assets were valued at $204.06 million while shareholder equity stood at $-6506000.00.

Athenex Inc ended 2024 with $0 in deferred long-term liabilities, $114.88 million in other current liabilities, 9000.00 in common stock, $-1016839000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $35.62 million and cash and short-term investments were $36.69 million. The company’s total short-term debt was $39,214,000 while long-term debt stood at $93000.00.

Athenex Inc’s total current assets stands at $124.93 million while long-term investments were $0 and short-term investments were $1.07 million. Its net receivables were $27.87 million compared to accounts payable of $33.68 million and inventory worth $42.65 million.

In 2024, Athenex Inc's operating cash flow was $0 while its capital expenditure stood at $56000.

Comparatively, Athenex Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.01
52-Week High
$23.8
52-Week Low
$0.081
Analyst Target Price
$2.25

Athenex Inc stock is currently trading at $0.01 per share. It touched a 52-week high of $23.8 and a 52-week low of $23.8. Analysts tracking the stock have a 12-month average target price of $2.25.

Its 50-day moving average was $0.16 and 200-day moving average was $2.23 The short ratio stood at 5.24 indicating a short percent outstanding of 0%.

Around 973.3% of the company’s stock are held by insiders while 2987.4% are held by institutions.

Frequently Asked Questions About Athenex Inc

The stock symbol (also called stock or share ticker) of Athenex Inc is ATNX

The IPO of Athenex Inc took place on 2017-06-14

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
$98.06
-2.59
-2.57%
$166.92
-3.6
-2.11%
$275.4
-17.05
-5.83%
RRIL Limited (531307)
$22.52
1.05
+4.89%
$130.7
-3.5
-2.61%
$310.85
-9.65
-3.01%
$0.04
0
+5%
$3.64
-0.25
-6.51%
$71.06
-0.31
-0.43%
$19.35
0.09
+0.47%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through Oncology Innovation Platform and Commercial Platform segments. The company’s Orascovery product candidates include Oral paclitaxel and encequidar for the treatment of metastatic breast cancer. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company engages in developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinoma. Further, it engages in developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York. On May 14, 2023, Athenex, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.

Address

Conventus Building, Buffalo, NY, United States, 14203